A new review is taking a look at the rationale and evidence for using a multidrug approach in pulmonary arterial hypertension (PAH), which the researcher says has a trajectory of progress that is exemplary among cardiopulmonary diseases. There are currently 14 approved therapies for the treatment of PAH, all of which target nitric oxide signaling (soluble guanylyl cyclase stimulator and phosphodiesterase type-V inhibitor [PDE-Vi] classes), the endothelin receptor axis (selective ETA and non-selective ETA/B antagonists), and the prostacyclin pathways (prostaglandin-I2 replacement or counter-receptor agonism). When it comes to multidrug treatment in PAH using the 14 available therapies, they are either used sequentially or combined upfront. Continue reading →

Hypertension is a major global public health concern and continues to be the leading cause of premature cardiovascular morbidity and death. In the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline update for hypertension, the threshold for defining hypertension was lowered, meaning many more people meet the threshold which now defines hypertension. Patients with diabetes have high cardiovascular risk and frequently have hypertension, says Matthew J Continue reading →

MONDAY, Dec. 7, 2020 (HealthDay News) -- In the past 30 years, U.S. Continue reading →

Metformin was found to be well-tolerated and safe for the treatment of pulmonary atrial hypertension (PAH), according to study results published in the Journal of the American Heart Association. In this single-center, open-label, mechanistic phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT01884051), 20 patients (mean age, 4210 years; 85% women; mean body mass index, 306 kg/m2) with heritable idiopathic PAH were recruited from Vanderbilt University Medical Center and given 2 g/day of metformin Continue reading →

December 08, 2020 07:00 ET | Source: Skylight Health Group Inc. Continue reading →

Indore: As everyone is prone to Covid-19, those suffering from diabetes and hypertension are more susceptible of the disease and its consequences. Continue reading →

Hypertensive heart disease: High blood pressure is one of the leading causes of heart disease Hypertension or high blood pressure is known as a silent killer as it increases the risk of heart disease significantly. Hypertensive heart disease refers to conditions that are caused by high blood pressure. Continue reading →

Background:Chronic inflammation in rheumatoid arthritis (RA) can induce reduced muscle mass (myopenia) and ectopic fat deposition probably showing normal body mass index (BMI). We aimed to investigate their body composition (BC) characteristics and clinical significance Continue reading →

Patients with COVID-19 and end-stage renal disease were 11 times more likely to be admitted to the hospital than patients without kidney disease. Continue reading →